ERBB2 and neoplasm: In addition to HER2, nanobody-based TRNT platforms targeting other tumor antigens (such as CD20, CS1, fibroblast activation protein-α and macrophage targets) have exhibited both direct radiation-induced cytotoxicity and immune activation, including increased CD8+ T cell infiltration and PD-L1 upregulation [226, 234, 235].